The future of cancer drug development is likely to be shaped by advances in genomics and personalized medicine. The ability to tailor treatments based on an individual’s genetic makeup holds great promise for improving outcomes. Additionally, the integration of artificial intelligence and machine learning into research and development processes is expected to accelerate the discovery of new drugs and optimize clinical trial designs.
